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radiotherapy, with the aim to verify possible correlations 
between the planned dose distributions to the main dose 
limiting structures and the observed levels of toxicity like 
mucositis, xerostomia and dysphagia. 
 
Material and Methods: Data of hystologically confirmed 
advanced HNC patients, in stage III and IV (AJCC), were 
reviewed in a retrospective dosimetric and clinical 
evaluation. Patients were treated with VMAT (RapidArc) and 
SIB in 33 fractions for a total dose of 69.96 Gy to the tumor 
and positive-nodes, and 54.45Gy to the elective volume, 
respectively. Toxicity was graded according to CTCAE3.0 
Correlation was explored between OAR dose parameters and 
related acute and late toxicities. 
 
Results: From December 2008 to August 2014, 102 patients 
were treated. Acute mucosal and swallowing toxicities higher 
than grade 3 were reported in only 11% and 6% of patients, 
respectively; late morbidities (G1-G2) were present in only 
3% of cases. No G3 Toxicity was reported. A statistically 
significant correlation was found between the dosimetric 
parameters of oral cavity V30Gy, V40Gy, and V70Gy, and 
mucosal toxicity (p = 0.01, 0.03, and 0.05, respectively). 
Concerning salivary glands, late toxicity profile was worse 
compared to acute side effects, with 19% of persisting late 
grade equal or higher than 2. Regarding the constrictors and 
the swallowing toxicity, most of the dosimetric parameters of 
the inferior constrictor muscle (mean dose, D1/2V, D1/3V, 
D2/3V) were significant at the univariate analysis, while no 
correlations were found for middle and superior constrictors. 
With a median follow-up of 19 months (range 1-61 months), 
Overall Survival (OS) at 3 and 5 years was 83%±4% and 
73%±10%. Mean OS was 51±3 months. Disease Free Survival 
(DFS) at 3 and 5 years was 71%±7%, and 34%±16%. Mean DFS 
was 43±3 months. 
 
Conclusion: Volumetric modulated arc therapy (VMAT) with 
Simultaneous Integrated Boost (SIB), that allow a shorter 
overall treatment time, a dose escalation, associated with a 
better sparing of OARs, showed a good toxicity profile. From 
our analysis toxicity to dose-limiting structures was 
significantly correlated to the dosimetric parameters 
explored. 
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Purpose or Objective: To investigate the association 
between temporally robust domains of patient-reported 
trismus symptoms with mouth-opening ability as assessed by 
maximal interincisal opening distance (MIO) in head and neck 
cancer (HNC) patients treated with radiotherapy (RT). 
 
Material and Methods: The study included 196 patients 
previously treated with primary state-of-the-art RT for HNC 
in 2007-2012. A five answering-category-based 
(no/mild/moderate/severe/very severe symptom) patient-
reported trismus questionnaire (Gothenburg Trismus 
Questionnaire, GTQ) was completed pre-RT, and at 3, 6, and 
12 months post-RT. This study focuses on the 14/21 
potentially RT-induced physical trismus symptoms from GTQ. 
At each follow-up, symptom domains were generated by 
means of factor analysis and these symptoms were correlated 
with MIO (categorized into five intervals (mm): 1: >50; 2: 
>40-≤50; 3: >35-≤40; 4: >25-≤35; 5: ≤25) for each follow-up 
using Pearson’s correlation coefficient (Pr). 
 
Results: The three symptom domains Jaw aches/pains, Jaw-
related problems, and Eating limitations were identified at 
each follow-up, and included one, two and three temporally 
robust symptoms, respectively. Correlations between MIO and 
these symptoms were weak to modest (Pr= 0.22-0.58; Table) 
with the overall stronger correlations for ‘Opening mouth 
difficulty’ and ‘Current mouth-opening ability’ in the Jaw-
related problems domain at 6 and at 12 months post-RT 
(Pr=0.49-0.58; Figure). 
 
 
 
 
 
Conclusion: Mouth-opening distances can be explained in 
terms of associated patient-reported symptom severities on 
jaw-related problems. Translating the patient’s experience 
into objective measurements and vice versa widens 
possibilities to monitor and possibly prevent progression of 
trismus symptoms after RT. 
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Purpose or Objective: Determination of expression of EGFR 
in premalignant and malignant lesions of the oral cavity and 
evaluating the role of Gefitinib in the same 
 
Material and Methods: 130 Patients with premalignant and 
malignant lesions of oral cavity from JK cancer institute, 
Kanpur were selected. EGFR status evaluation was done in all 
the patients. Premalignant lesions over expressing EGFR were 
observed for transformation into malignant lesions and were 
given Tab Gefitinib 250 mg OD daily. Malignant lesions with 
over expression of EGFR were randomly divided into 2 groups 
first group consisted of patients who were given 
CCRT(cisplatin). The other group had the same regimen but 
with the addition of Tab Gefitinib 250 mg daily 
 
Results: Out of 130 patients registered 53 were premalignant 
out of which EGFR(+) positive in 73%( 39) patients. EGFR( 
++)over expression were in 8%(4)patients, EGFR negative in 
18%(10) patients. 77 were malignant lesions EGFR positive in 
89%(51) patients. EGFR(+)in 38%(27) of patients, EGFR(++)in 
40%( 28) patients ,EGFR(+++) were expressed by 11%( 11) 
patients. EGFR negative in 11%(11 patients) 
